Dr. Stephen Oh is assistant professor in the Division of Hematology at Washington University School of Medicine in St. Louis. Dr. Oh heads a translational research group focused on the pathogenesis of myeloproliferative neoplasms (MPNs) with the goal of translating the work into improved therapies for MPN patients. He completed his MD and PhD at Northwestern University’s Feinberg School of Medicine in Chicago, Illinois. Dr. Oh went on to complete a residency, fellowship and postdoctoral fellowship at Stanford University School of Medicine in Stanford, California. Dr. Oh discloses that he has received research support from Incyte Corporation, Gilead Sciences, Inc., CTI BioPharma, and Janssen. He has served as an advisory board member for Incyte Corporation and Gilead.